title: Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey.
abstract: BACKGROUND
  There are no country-based data focused on aspirin (ASA)-exacerbated respiratory disease (AERD) in Turkey.
  
  
  OBJECTIVE
  To assess the prevalence of AERD in adult patients with asthma.
  
  
  METHODS
  A structured questionnaire was administered via face-to-face interview by a specialist in pulmonology/allergy at seven centres across Turkey.
  
  
  RESULTS
  A total of 1344 asthma patients (F/M: 1081/263: 80.5%/19.5%, mean age: 45.7 ± 14.2 years) were enrolled. Atopy rate was 47%. Prevalence of allergic rhinitis, chronic rhinosinusitis/rhinitis, and nasal polyposis (NP) were 49%, 69% and 20%, respectively. Of 270 patients with NP, 171 (63.3%) reported previous nasal polypectomy and 40 (25%) had a history of more than three nasal polypectomies. Aspirin hypersensitivity was diagnosed in 180 (13.6%) asthmatic patients, with a reliable history in 145 (80.5%), and oral ASA provocation test in 35 (19.5%) patients. Clinical presentations of ASA hypersensitivity were respiratory in 76% (n=137), respiratory/cutaneous in 15% (n=27), and systemic in 9% (n=16) of the patients. Multivariate analysis indicated that a family history of ASA hypersensitivity (p: 0.001, OR: 3.746, 95% CI: 1.769-7.929), history of chronic rhinosinusitis/rhinitis (p: 0.025, OR: 1.713, 95% CI: 1.069-2.746) and presence of NP (p<0.001, OR: 7.036, 95% CI: 4.831-10.247) were independent predictors for AERD.
  
  
  CONCLUSIONS
  This cross-sectional survey showed that AERD is highly prevalent among adult asthmatics and its prevalence seems to be affected by family history of ASA hypersensitivity, history of rhinosinusitis and presence of NP.
authors: Ankara University, School of Medicine, Department of Chest Diseases, Division of Immunology and Allergy, Turkey. bavbek@medicine.ankara.edu.tr
authors: S
authors: S
authors: Bavbek
authors: I
authors: I
authors: Yilmaz
authors: G
authors: G
authors: Celik
authors: O
authors: O
authors: Aydin
authors: F Ö
authors: FÖ
authors: Erkekol
authors: A
authors: A
authors: Orman
authors: E
authors: E
authors: Kurt
authors: D
authors: D
authors: Ediger
authors: B
authors: B
authors: Dursun
authors: O
authors: O
authors: Abadoğlu
authors: F
authors: F
authors: Ozşeker
authors: E
authors: E
authors: Akkaya
authors: G P
authors: GP
authors: Karakiş
authors: S
authors: S
authors: Canbakan
authors: S
authors: S
authors: Yüksel
authors: Z
authors: Z
authors: Misirligil
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D001249:Asthma / Q000453:epidemiology / Q000503:physiopathology; D055963:Asthma, Aspirin-Induced / Q000453:epidemiology; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000453:epidemiology / Q000503:physiopathology; D015995:Prevalence; D011379:Prognosis; D012140:Respiratory Tract Diseases / Q000453:epidemiology* / Q000503:physiopathology*; D012220:Rhinitis / Q000453:epidemiology / Q000503:physiopathology; D012307:Risk Factors; D012852:Sinusitis / Q000453:epidemiology / Q000503:physiopathology; D014421:Turkey / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin